Biotech companies drew an estimated $4.9 billion in fresh capital during the first full week of January, according to Endpoints News and other market tallies. The inflows included multiple mega-rounds for private startups and a cluster of venture and crossover deals timed before the JP Morgan Healthcare Conference. Investors pushed capital into discovery-stage platforms, clinical-stage biotechs and supporting infrastructure, underscoring renewed appetite for early and mid-stage assets. The wave is concentrated in companies pursuing oncology, genetic medicines and AI-enabled discovery tools. Source coverage: Endpoints News and BioCentury market reports. For industry participants, the short-term effect is increased runway for program advancement and potential pressure on valuations at the next financing steps; longer-term impacts depend on data flow from these newly funded programs.